Disease Targeting Properties of Voclosporin in Kidney Transplant and Lupus Nephritis Patients (KIDNEY WEEK 2024) - Sep 23, 2024 - Abstract #TH-PO642; Pres time: Oct 24, 2024; 10:00 AM - 12:00 PM; Location: Exhibit Hall, Convention Center; "VCS does not require therapeutic drug monitoring, and is associated with improved glucose, lipid and electrolyte profiles compared to tacrolimus and cyclosporine. The larger peripheral volume of distribution indicates selective peripheral tissue uptake of VCS in patients with renal transplant and LN. This is consistent with immunosuppressive activity of VCS in targeted organs relative to blood circulation. The low blood levels of VCS are consistent with the safety profile of VCS compared to other calcineurin inhibitors."
Clinical • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • Transplantation
|
|
Simon Zhou, PhD; Linda M. Rehaume, PhD; Ernie Yap, MD; Henry Leher, PhD; Lucy S. Hodge, PharmD, PhD; Robert B. Huizinga, PhD, RN
|